文献速递主动脉疾病

BeGraft支架作为开窗EVAR桥接支架的前瞻性多中心医生发起试验

Prospective, Multicentre Physician Initiated Trial Investigating the BeGraft Stent Graft as Bridging Stent in Fenestrated Endovascular Aortic Repair for Complex Aortic Aneurysms.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2026-02-03

12个月技术成功率98.3%,桥接支架一期通畅率99.3%,无桥接支架相关内漏99.6%,无桥接支架相关再干预97.1%。

要点

  • BeGraft作为开窗EVAR桥接支架12个月一期通畅率达99.3%。
  • 12个月无桥接支架相关内漏为99.6%,无相关再干预为97.1%。
  • 仅报告2例器械缺陷和2例桥接支架堵塞,无>10mm迁移。

核心结论

  • BeGraft支架作为开窗EVAR的桥接支架显示出良好的短期结局,一期通畅率高且桥接支架相关并发症发生率低。

主要发现

  • 技术成功率为98.3%,12个月内报告2例桥接支架堵塞,12个月一期通畅率为99.3%。
  • 无手术相关并发症比例为88.3%,12个月无桥接支架相关内漏为99.6%,无桥接支架相关再干预为97.1%。
  • 发生2例器械缺陷:1例为释放前桥接支架与球囊断开,1例为术后1年桥接支架断裂;试验期间未记录到>10mm的桥接支架迁移。

关键数值与推荐

  • 主要终点为技术成功、桥接支架通畅、12个月无手术相关并发症及无桥接支架相关内漏。
  • 技术成功98.3%,12个月一期通畅率99.3%,无手术相关并发症88.3%,无桥接支架相关内漏99.6%,无桥接支架相关再干预97.1%。

临床怎么用

  • 对于复杂主动脉瘤行开窗EVAR,BeGraft支架可作为桥接支架选择,短期通畅率高且相关并发症和内漏发生率低。

局限性

  • 为单臂研究,无对照组;随访时间限于短期(12个月);BeGraft支架为超适应证使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report the early results of a physician initiated clinical trial evaluating the safety and performance of the BeGraft Stent Graft (Bentley InnoMed, Hechingen, Germany) in fenestrated endovascular aortic aneurysm repair (FEVAR). METHODS: This prospective, multicentre, single arm, physician initiated trial enrolled patients undergoing FEVAR for complex aortic aneurysms between March 2021 and July 2022 in nine high volume German centres. The BeGraft Stent Graft was used outside its initial intended use as a bridging stent graft (BSG) for FEVAR. The primary endpoints were technical success, BSG patency, and absence of procedure related complications and BSG related endoleaks at 12 months. RESULTS: One hundred and three patients were prospectively enrolled. Three hundred and fifty BSGs were implanted as investigational devices and were included in the analysis. Technical success was 98.3%. Two BSG occlusions were reported in the first 12 months. Primary patency at 12 months was 99.3%. The absence of procedure related complications was 88.3%. Freedom from BSG related endoleaks at 12 months was 99.6%. Freedom from BSG related re-interventions was 97.1%. Two device deficiencies occurred in two patients: one disconnection between the BSG and the balloon before deployment, and one BSG fracture at one year. No BSG migration > 10 mm was recorded during the trial period. CONCLUSION: This study demonstrated favourable short term outcomes of the BeGraft Stent Graft as a BSG in FEVAR with good primary patency and low rates of BSG related complications.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Marques de Marino P, Kotelis D, Gombert A, et al. Prospective, Multicentre Physician Initiated Trial Investigating the BeGraft Stent Graft as Bridging Stent in Fenestrated Endovascular Aortic Repair for Complex Aortic Aneurysms. Eur J Vasc Endovasc Surg. 2026. PMID: 41638548. doi:10.1016/j.ejvs.2026.01.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。